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1. Introduction 
Epilepsy affects nearly 50 million people worldwide and is a disease that involves 
spontaneous frequent seizures caused by electrical disturbances in the brain (Bergen 1998; 
Meinardi, Scott et al. 2001). Epilepsy is a syndrome, or a collection of symptoms, in which 
people are predisposed to seizures (Fisher, van Emde Boas et al. 2005; Gomez-Alonso and 
Giraldez 2007; Jaseja 2009). Epilepsy diagnosis usually occurs after permanent injury to the 
brain or from inborn errors that cause brain tissue to become abnormally excited (Fisher, 
van Emde Boas et al. 2005). Health statistics show that children less than 2 and adults older 
than 65 are the most likely populations to develop epilepsy and that seizure events increase 
the risk of mortality in the individual (Feng 1978; Tsai 2005; Fountain, Van Ness et al. 2011). 
It is thought that nearly 4% of the US population will have seizure activity in their lifetimes, 
with many having seizures and never being aware they occurred.  
In some types of epilepsy, the cause of the seizures cannot be clearly defined and does not 
present with other neurological disorders (Lerman, Sagie et al. 2011). Certain types of epilepsy 
have a genetic component (Poduri and Lowenstein 2011; Sisodiya and Mefford 2011; Sozmen, 
Baybas et al. 2011; Wilke, Worrell et al. 2011), but the most common diagnoses of epilepsy 
occur after neurological damage such as a stroke, transient ischemic attacks, a diagnosis of 
dementia, traumatic brain injury, brain abscesses, meningitis, encephalitis, neurosyphilis, brain 
tumors, hematomas, abnormal blood vessels, AIDS, congenital brain defects, metabolic 
diseases such as phenylketonuria, and liver or kidney failure.  
Epileptic seizures range in severity from staring spells to violent convulsions and loss of 
consciousness (Haut, Lipton et al. 2005; Maillard, Vignal et al. 2009). Given the wide variety 
of factors that can precipitate epilepsy, it stands to reason that type of seizure is dependent 
on the location and type of the brain injury. Upon physical examination, many people 
suffering from epilepsy appear healthy (Maganti, Gerber et al. 2008). Most epileptics will 
present with clinical abnormal electrical activity as measured by an electroencephalograph 
(Urbach 2005). Epilepsy is further classified as idiopathic (presumed genetic basis), 
symptomatic (due to a structural abnormality) or cryptogenic (cause is undetermined) 
(Kwan and Brodie 2000; Berg and Kelly 2006; Farrell, Wirrell et al. 2006).  
Unfortunately, after some epileptic events, there is a risk of neuron destruction.  This is 
especially concerning due to the limited capacity of the brain to regenerate neurons and 
oftentimes, the damage is permanent. Following a seizure, epileptic’s brains often form 
excitotoxic lesions which destroy neurons by initiating apoptosis. The current treatment for 
epilepsy is limited to controlling the seizure activity. Anticonvulsants are oral medications 
used to prevent seizures in patients with epilepsy. The specific drug prescribed to patients 
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varies based on their past seizure history and any underlying conditions that may have 
contributed to the epileptic diagnosis. (Prunetti and Perucca 2011; Steinert, Baier et al. 2011; 
Strzelczyk, Cenusa et al. 2011; Verrotti, Loiacono et al. 2011; Yasuda, Sugiura et al. 2011). In 
patients with epilepsy resulting from chronic infections, the epileptic symptoms will subside 
after the course of drug treatment. Also, epilepsy occurring after tumor development or 
following injury to blood vessels, such as a hematoma, can be successfully managed in some 
cases after the underlying cause of injury is treated. Nevertheless, it is difficult to treat these 
types of brain injuries; so many patients  use proper medication to prevent the seizures 
(Sander 1993).  
The cases of epilepsy that do not respond to medication (Go and Snead 2008; Berg 2009; 
Nakken and Tauboll 2009), are often candidates for invasive and risky procedures such as 
brain surgery. Surgery can remove the damaged cells of the brain which cause the abnormal 
electrical signals. Other surgical procedures such as implantation of a device, similar to a 
heart pacemaker, stimulate the vagal nerve and help reduce the frequency of seizures 
(Landre 2004). Unfortunately, there are also types of epilepsy that cannot be managed well 
with medication or any other available therapies and the general term for this type of 
epilepsy is called refractory or intractable epilepsy (Sander 1993; Kwan and Brodie 2000; 
Lerman, Sagie et al. 2011). Growing lines of evidence have indicated a role of inflammation 
in causing and exacerbating intractable epilepsy (Vezzani, French et al. 2011). Patients with 
intractable epilepsy often go on specialized diets which are thought to help reduce the 
severity and number of seizures. Popular diet choices for epileptic patients are diets low in 
carbohydrates, such as the ketogenic diet (Kossoff and McGrogan 2005), which is very low 
in carbohydrates and very high in fat but still calorie balanced for the individual. For 
undetermined reasons, when the body of an epileptic burns fat for fuel, rather than glucose, 
it can help control and prevent seizures (Baranano and Hartman 2008; Choragiewicz, 
Zarnowska et al. 2010; Westmark, Westmark et al. 2010). While the ketogenic diet is 
effective, long term health implications prevent patients from being on the diet for periods 
longer than two years (de Kinderen, Lambrechts et al. 2011). Dietary antioxidants are known 
to protect against seizures possibly by increasing the free radical scavenging capabilities of 
key antioxidant enzymes in the brain (Garjani, Fathiazad et al. 2009; Mehla, Reeta et al. 2010; 
Militao, Ferreira et al. 2010; Pages, Maurois et al. 2010; Sharma, Nehru et al. 2010; Tome Ada, 
Ferreira et al. 2010). Using a nutrigenomics approach to identify compounds with a 
beneficial effect (Suzuki 2011), researchers can identify genes associated with epilepsy 
susceptibility and then test whether particular dietary components, in this case selenium, 
can be used to improve the incidence, frequency, and severity of epilepsy and the resulting 
complications. 
2. Selenium and selenoproteins 
Selenium is a non-metal trace element discovered in 1817 as a by-product of sulfuric acid 
production (Brown and Arthur 2001). Selenium exists in nature in organic (such as 
selenomethionine and selenocysteine) or inorganic (such as selenate and selenite) forms 
(Puzanowska-Tarasiewicz, Kuzmicka et al. 2009).  
Selenium can be incorporated non-specifically into methionone-rich proteins, such as those in 
the Brazil nut and sunflower seeds (Kortt, Caldwell et al. 1991). The biological functions of 
selenium are mainly mediated by selenoproteins, which contain selenocysteine (Allmang, 
Wurth et al. 2009; Lu and Holmgren 2009). Selenocysteine (Sec) has its own tRNA and its own 
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codon, UGA (de Jesus, Hoffmann et al. 2006). Sec is inserted into mRNA in response to UGA 
codons in the genome of all selenoproteins. Selenoprotein mRNA is characterized by 
selenocysteine insertion sequence element (SECIS) (Howard, Moyle et al. 2007; Mix, Lobanov 
et al. 2007), and a RNA-binding protein complex (Bock, Forchhammer et al. 1991; Small-
Howard and Berry 2005; Allmang and Krol 2006; Squires and Berry 2008). Some selenium-
containing proteins such as the liver protein 56K and the liver fatty acid binding protein 
(Behne, Weiss-Nowak et al. 1994) can sequester Se, but they do not contain selenocysteine. 
Selenium was only recognized as a toxicant (Belogorsky and Slaughter 1949; Fels and 
Cheldelin 1949; Klug, Harshfield et al. 1952; Mc and Portman 1952; Fabre and Truhaut 1956) 
and its biological role was unknown until 1952 when its essential role was discovered in 
microorganisms. It is a trace mineral that is essential for humans (Papp, Lu et al. 2007), 
which was first recognized when when dietary supplementation of selenium prevented 
liver necrosis in rats efficiently (Mertz and Schwarz 1958; Schwarz, Stesney et al. 1959; 
Schwarz, Porter et al. 1972). Following these studies, it was found that selenium was 
essential for glutathione peroxidase (GPX) activity (Flohe, Gunzler et al. 1973; Rotruck, Pope 
et al. 1973). Sec, now identified as the 21st amino acid was indentified in eubacteria and 
archaebacteria model systems (Ambrogelly, Palioura et al. 2007; Xu, Carlson et al. 2007). 
Stadtman and colleagues found that selenium was incorporated into proteins in the form of 
selenocysteine through labeled Clostridium sticklandii with 75Se metabolically (Cone, Del Rio 
et al. 1976; Axley and Stadtman 1989; Lee, Worland et al. 1989; Leinfelder, Stadtman et al. 
1989; Stadtman, Davis et al. 1989). UGA, the stop codon, was discovered for selenocysteine 
incorporation in murine and GPX1 gene was cloned at the same time (Chambers, Frampton 
et al. 1986). 
Selenium deficiency (Kakturskii, Strochkova et al. 1990), or Keshan disease, is responsible 
for the cardiomyopathy in children living in parts of China where the soil lacks selenium 
(Guanqing 1979; Yang and Xia 1995; Yang, Chen et al. 2007). Recently, the gene of Secisbp2 
protein, which is related with synthesis of selenoproteins (Copeland and Driscoll 1999; 
Copeland, Fletcher et al. 2000; Low, Grundner-Culemann et al. 2000; Tujebajeva, Copeland 
et al. 2000; Berry, Tujebajeva et al. 2001; Copeland and Driscoll 2001; Copeland, Stepanik et 
al. 2001; Fletcher, Copeland et al. 2001; Copeland and Driscoll 2002; Lescure, Allmang et al. 
2002; Lescure, Fagegaltier et al. 2002), has been studied as a possible target for hereditary 
diseases, an example of which includes human thyroid hormone metabolism disorder 
(Dumitrescu, Liao et al. 2005). Selenium is also known as an important chemoprevention 
agent (El-Sayed, Aboul-Fadl et al. 2006; Micke, Schomburg et al. 2009) by inducing apoptosis 
in cancer cells (Jackson and Combs 2008) and senescence in the early stage of tumorigenesis 
(Wu, Kang et al. 2010) in a dose-dependent manner. 
More than 50 years ago, the ROS (reactive oxygen species) theory of aging was proposed. 
However, there is still there is a lack of irrefutable evidence in support or opposition of this 
theory. ROS can be induced by exogenous sources, such as UV or ionizing irradiation 
(Finkel 2000), which are by-products of mitochondrial respiration and widespread in vivo as 
the form of superoxides, hydroxyl free radicals, and hydrogen peroxides (Harman, 1956). As 
previous studies have shown, GPX1 contributes much of the H2O2-eliminating activity of 
selenium (Cheng, Ho et al. 1997; Cheng, Ho et al. 1997; Lei, Cheng et al. 2007). Therefore, it 
is logical to address the ROS theory of aging through investigation of selenium and 
selenoproteins (Hawkes and Alkan 2010). Some studies have implied that the accumulation 
of lipid oxidation in mitochondria has the potential to suppress the increased activity of 
GPX when comparing aged and juvenile rats (Nohl, Hegner et al. 1979). However, there is 
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no conclusive evidence to identify the biological function of GPX1 in lifespan extension in 
mouse models (Ladiges, Van Remmen et al. 2009). Interestingly, GPX4-/- mice are embryonic 
lethal while GPX4+/- mice displays lifespan extension (Ran, Liang et al. 2007). 
Most of the selenoproteins that have been identified are enzymes with selenium in their 
active sites. Through scanning the whole human genome to find SECIS, a total of 25 
selenoproteins were discovered (Kryukov, Castellano et al. 2003), which contain five 
glutathione peroxidases (GPX1-4, GPX6), three thioredoxin reductases (TR1-3) (Hondal and 
Ruggles 2010), three iodothyronine deiodinases (DI-III), the 15-kDa selenoprotein (Sep 15), 
selenophosphate synthetase-2 (SPS2), and selenoprotein H, I, K, M, N, O, P, R, S, T, U, V. All 
selenoproteins only have one selenocysteine residue except for selenoprotein P which 
contains 10 residues (Burk and Hill 1999). The domains containing selenocysteine residues 
in selenoprotein are highly related with their enzyme activities (Hill, Zhou et al. 2007). It 
was noted that cysteine replacing the selenocysteine residue in selenoproteins lead to 
reduction of catalytic activity (Hazebrouck, Camoin et al. 2000; Lee, Bar-Noy et al. 2000; 
Korotkov, Novoselov et al. 2002; Kryukov and Gladyshev 2002).  
Notably, more than one-third of selenoproteins play a critical role in combating oxidative 
stress. The GPX family uses glutathione as a reducing equivalent to eliminate hydrogen 
peroxide, organic hydroperoxides and phospholipid hydroperoxides (Bosch-Morell, Flohe et 
al. 1999; Flohe, Hecht et al. 1999). The redox status of thioredoxin is under the control of the 
thioredoxin reductase (TR) family (Bjornstedt, Hamberg et al. 1995; Holmgren and 
Bjornstedt 1995). Sel P is thought to be not only a selenium carrier, which distributes in body 
fluids, but capable of eliminating phospholipid hydroperoxides (Saito, Hayashi et al. 1999; 
Takebe, Yarimizu et al. 2002). It is important to elucidate the mechanism by which 
selenoperoxidases eliminate ROS in the brain and to identify additional selenoperoxidases 
and their functions during aging and neuron degeneration. 
3. Selenium and selenoproteins in epilepsy  
The brain expresses most selenoproteins and is at the apex of selenium retention in the body 
(Nakayama, Hill et al. 2007). It is proposed that selenium may be necessary for prevention of 
epilepsy or other degenerative neurological disorders; however, there is no consensus in the 
field whether selenium plays a direct role or not. Selenium has a role in protection the 
neurons from excitotoxic insults, such as the continuous stimulation of a nerve cell by 
glutamate or another neurotransmitter, and thus can decrease the insult burden on the 
neurons (Savaskan, Brauer et al. 2003).  
Although no severe neurological phenotypes have been associated with a selenium deficient 
diet, this may be due to the brain’s preferential sequestration of body selenium. Mice on a 
selenium deficient diet are, however, more susceptible to neuropathological changes (Hill, 
Zhou et al. 2004). It is not well known how selenium status in the blood and the brain are 
correlated (Chen and Berry 2003), but it is known that selenium supplementation can 
prevent dopamine loss and degeneration of neurons in the substantia nigra, and reduce 
lipid peroxidation (Aldeeb, Almoutaery et al. 1995; Imam, Newport et al. 1999; Zafar, 
Siddiqui et al. 2003). Selenium was shown to protect the neurons through selenoproteins 
(Savaskan, Brauer et al. 2002; Lamarche, Signorini-Allibe et al. 2004; Reeves, Bellinger et al. 
2010; Wang, Geng et al. 2010) and other studies that combine selenium treatment with 
anticonvulsant medication showed a synergistic protective effect against induced seizures 
(Kutluhan, Naziroglu et al. 2009). Also, in cases of selenium deficiency, neurons are exposed 
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to increased glutamate-induced excitotoxicity because selenium has an inhibitory effect on 
the glutamate induced NF-B and AP-1 activation (Savaskan, Brauer et al. 2002; Santamaria, 
Vazquez-Roman et al. 2005). 
There are a total of 24 selenoproteins in mice, all of which are expressed in the brain, 
particularly in neurons of the olfactory bulb, hippocampus, cerebral cortex and cerebellar 
cortex (Zhang, Zhou et al. 2008). In these tissues Gpx4, Sel K, Sel M, Sel W, and Sel 15 mRNAs 
were expressed the most, but in the choroid plexus over half of the identified selenoproteins 
were expressed. Gpx4, Sel P, and Sel W genes were highly expressed in over 90% of the brain, 
similar to findings from previous studies that found Sel P and Sel W were highly expressed 
in the rodent brain (Dreher, Schmutzler et al. 1997; Steinert, Bachner et al. 1998; Sun, Butler 
et al. 2001; Hoffmann, Hoge et al. 2007; Nakayama, Hill et al. 2007; Renko, Hofmann et al. 
2009).  
There are some regions of the rodent brain that express significantly lower levels of 
selenoproteins, which implies that some structures of the brain are less dependent on 
selenium availability. Selenoprotein genes are expressed the lowest in the oculomotor 
nucleus, Edinger-Westphal nucleus, nucleus Raphé pontis, anteroventral periventricular 
nucleus and dorsal premammillary nucleus; however, these brain regions do express the 
same selenoproteins that are found to be highly expressed in other regions of the brain, but 
at a significantly lower level, such as Sel P, and Sel W and Gpx 4 (Zhang, Zhou et al. 2008). In 
the white matter of the brain, or corpus callosum, selenoprotein expression is considerably 
less than in other regions of the brain. The corpus collosum consists of mainly myelinated 
axons and is responsible for carrying the nerve impulses to different regions of gray matter.  
Generation of ROS and the resulting oxidative stress are known to be both the cause and 
consequence of many neurodegenerative conditions (Sander 1993). Post mortem autopsies 
of people with the neurodegenerative disorders Parkinson’s disease, Alzheimer’s disease, 
and amyotrophic lateral sclerosis all show that there are increased ROS in the regions of 
the brains that were affected by the neurodegenerative disorder. The brain has a reduced 
capacity for regeneration and a high metabolic rate which predisposes it to oxidative 
damage. The repair mechanisms that the cells have employed to counteract oxidative 
damage are primarily antioxidant enzymes such as glutathione peroxidases and 
thioredoxin reductases which are dependent on selenium for their function. Accumulating 
lines of evidence suggest that selenium-dependent antioxidant enzymes and 
selenoproteins are integral to epilepsy and have a role in the progression of the disease. It 
is promising to use selenium as a line of treatment against degenerative free radical 
diseases such as epilepsy.  
3.1 The Se-dependent glutathione peroxidase  
The function of the GPX family is to remove hydrogen and other peroxides from the brain 
and other tissues by coupling its reduction to water and alcohols using glutathione as a 
reducing equivalent. Glutathione is found in the mitochondria and cytoplasm of brain tissue 
and has been found to be released into the extracellular space by astrocytes. Interestingly, 
the first report of selenium status affecting any neurological condition was in infants with 
intractable epilepsy (Weber, Maertens et al. 1991). Infant brains are particularly susceptible 
to oxidative damage, which can contribute to abnormal brain electrical signaling, because of 
the high concentration of unsaturated fatty acids in the infant brain needed to synthesize 
cholesterol and fatty acids. These nutrients are necessary for the billions of developing nerve 
connections.  
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The seizure symptoms of these infants can be reversed with selenium supplementation 
(Weber, Maertens et al. 1991; Ramaekers, Calomme et al. 1994). Children suffering from 
intractable epilepsy are deficient in glutathione peroxidase activity. From the four children 
studied, two had normal blood selenium and high concentrations of GPX in their plasma, 
but low enzymatic activity. The other children had low intracellular selenium levels and low 
GPX expression and activity. Selenium supplementation and discontinuation of their 
anticonvulsant medication decreased seizure activity. The second study found that oral 
selenium supplements in children (3-5 g/kg body weight) decreased frequency of seizures, 
improved electroencephalograph recordings, and restored liver function in the infants after 
two weeks of treatment (Ramaekers, Calomme et al. 1994). It was thought that 
supplementation of selenium restored the function of selenium-dependent GPX1 and GPX4 
activity. From these results, selenium status is an important triggering factor for the onset of 
intractable seizures and that selenium-conferred antioxidant protection in the brain can help 
prevent neuronal damage following frequent seizures. 
It has been suggested that treatment with anticonvulsants, such as valproic acid, which 
induces oxidative stress, depletes total body selenium and decreases GPX activity 
(Naziroglu 2009). However, others believe that selenium supplementation in congruence 
with antiepileptic drugs increase the risk of systemic toxicity. The conflicting selenium levels 
are likely associated with the pharmacology of the particular drug, duration of treatment, 
age of subject, validity of plasma selenium estimating brain selenium concentrations, and 
the underlying cause of the patient’s epilepsy. It has been found that epileptic patients, 
without medication, have lower blood and tissue levels of selenium in addition to lower 
levels of selenoproteins and lower levels of selenium-dependent redox enzymes. In 
particular, intractable epileptics have been shown to have significantly lower mean serum 
selenium levels compared to a control group (Ashrafi, Shabanian et al. 2007). Animal 
models have shown that selenium can prevent the development of iron-induced epileptic 
symptoms due to selenium’s ability to combat peroxidative injury (Rubin and Willmore 
1980; Willmore and Rubin 1981). 
3.2 Thioredoxin reductases 
Thioredoxin reductases (TR) use NADPH for reduction of thioredoxin in various cellular 
redox pathways (Tamura and Stadtman 2002). TR-3 is expressed in very low levels in the 
mouse brain (Zhang, Zhou et al. 2008). Although TR-1 is well characterized and expressed 
in high levels in other organs, it is not highly expressed in the brain. Since TR is important 
for intracellular redox regulation and antioxidant defense (Schweizer, Brauer et al. 2004), 
decreased TR expression and activities could lead to enhanced cell loss, thus increasing the 
risk for epilepsy and other neurodegenerative conditions.  
3.3 Selenoprotein P 
Selenoprotein P (Sel P) is unique because it contains 10-17 selenocysteine residues, unlike 
other selenoproteins which contain only one. Sel P is produced mostly in the liver, but all 
tissues make and secrete Sel P into the plasma (Burk and Hill 2005; Hoffmann, Hoge et al. 
2007). In rodents, Sel P is a predominant form of selenium in the plasma. Sel P is responsible 
for selenium transportation throughout the body, particularly to the brain where selenium is 
needed for incorporation into other selenoproteins which confer antioxidant benefits (Hill, 
Zhou et al. 2007). Sel P knockout mice develop seizures and movement disorders when 
raised on selenium restricted diets. 
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During seizure activity in epileptics, the neurons in the affected areas of the brain often have 
redox shifts due to the large influx of calcium through voltage gated channels (Stefani, 
Spadoni et al. 1997). If cellular redox equilibrium is not quickly restored following seizures, 
it is probable that the neurons will die and that region of the brain will be unable to function 
properly (Wirth, Conrad et al. 2010). It is thought that selenium, probably through its 
function in the GPX or TR families, can help prevent neuronal cell death and neutralize ROS 
which is generated as a consequence of high intracellular calcium (Xiong, Markesbery et al. 
2007). Typically the brain can handle redox shifts and occasional electrolyte imbalances; 
however, during a seizure these activities happen at a rate and frequency that the cells 
cannot handle (Howse and Duffy 1975). The neurons eventually will die, and cause an 
increase in potentially harmful cellular byproducts (Barinaga 1998). 
3.4 Selenoprotein W 
Selenoprotein W (Sel W) has a redox motif and binds glutathione (Beilstein, Vendeland et al. 
1996; Whanger 2009), similar to the well characterized GPX family. The ‘W’ designation is 
because of the white muscle disease seen in grazing livestock in areas where the soil is 
depleted of selenium (Vendeland, Beilstein et al. 1993). Sel W is highly expressed in the four 
basic brain regions in rodents; the hippocampus, olfactory area, cerebellar cortex, and 
isocortex (Zhang, Zhou et al. 2008).  
The expression of Sel W is induced in the neurons of mesial temporal lobe epilepsy patients 
more than tenfold and is associated with BCL2 expression, which suggests that the Sel W 
induction is a defensive response to oxidative stress (Yuzbasioglu, Karatas et al. 2009). 
Furthermore, the expression of Sel W in cortex, cerebellum, and thalamus remains constant 
under Se deficiency (Sun et al., 2001b). Thus, Sel W expression is maintained in certain 
regions of the brain under selenium deficiency, suggesting a critical role of Sel W in the 
protection against seizure activities that is associated with increased oxidative stress. 
3.5 Selenoprotein H  
Selenoprotein H (Sel H) is a nucleolar DNA-binding protein (Novoselov, Kryukov et al. 
2007) and may function as a transcription factor (Panee, Stoytcheva et al. 2007). It has been 
found that Sel H mRNA is highly expressed in the hippocampus during development but 
level falls quickly after birth and is undetectable in the adult brain (Zhang, Zhou et al. 2008); 
however, in another study the Sel H gene was found to be expressed in the adult mouse 
brain by using the RT-PCR method (Hoffmann, Hoge et al. 2007). 
3.6 Selenoprotein M 
Selenoprotein M (Sel M) is a small endoplasmic reticulum protein with unknown function, 
which is highly expressed in cornu ammonis granule cells of dentate gyrus (Zhang, Zhou et 
al. 2008). Cornu ammonis is also known as Ammon’s horn and is part of the interlocking 
gyri which makes up the hippocampus. Interestingly, the most common form of 
neuropathological damage in temporal lobe epilepsy patients is sclerosis (hardening of 
tissue) of the cornu ammonis, also known as Ammon’s horn sclerosis, which is characterized 
by neuronal cell loss in the hippocampus region of the brain. Common clinical markers of 
the disease include granule cell dispersion, reactive gliosis, and the segmental loss of 
pyramidal neurons. Unfortunately, 65% of people with temporal lobe epilepsy suffer from 
this disease (Blumcke, Thom et al. 2002; de Lanerolle and Lee 2005). Many of the seizures 
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due to temporal lobe epilepsy are very poorly controlled with anticonvulsant drugs. The 
role of Sel M is not fully understood and it is unclear whether Ammon’s horn sclerosis is the 
cause of seizures of epileptics, or rather damage from the ongoing seizure activity.  
4. Selenium and neurological disorders 
Most inherited or congenital forms of epilepsy develop and occur before the age of 2. Older 
adults who have developed epilepsy have done so mostly because of brain injuries 
(hematomas and other bleeding vessels) or after a stroke. Generally, the most common cause 
of epilepsy in the elderly is attributed to cerebrovascular diseases or prescription drug 
reactions. Older populations are more at risk for drugs causing epileptiform activities 
because of their increased sensitivity to all drugs due to decreased drug metabolism.  
Also other diseases in the elderly, particularly those that cause impaired language function 
or overall neurological deterioration, have been associated with increased seizure risks. 
Other factors such as metabolic problems, uraemia, thyroid problems, low blood sugar, 
electrolyte imbalances and liver damage can all contribute to seizures in the older 
population. In addition to the metabolic risk factors, epilepsy risk can also increase in 
patients with neurological disorders such as Alzheimer’s (Noebels 2011), down syndrome, 
and dementia (Ito, Echizenya et al. 2009; Palop and Mucke 2009; Rao, Dove et al. 2009; 
Scarmeas, Honig et al. 2009; Larner 2010; Westmark, Westmark et al. 2010).  
There is a link between neurological disorders and aging (Zhang, Rocourt et al. 2010). Since 
the body preferentially retains selenium in the brain even during periods of selenium 
deficiency, which further implies that selenium plays an important role in the brain (Behne, 
Hilmert et al. 1988; Chen and Berry 2003). Neurological disorders such as Alzheimer’s 
disease, Parkinson’s disease, and those disease states resulting from damage caused by 
environmental toxins, ischemic insults, drug abuse, and brain tumors are exacerbated by 
ROS (Chen and Berry 2003). 
The selenium protection against neurological disorders is primarily conferred through 
antioxidative selenoproteins (Zhang, Rocourt et al. 2010). Therefore, selenoproteins play an 
important role in regulating redox reactions in the body, and particularly the brain. For 
example, the brains in mouse models of Alzheimer’s disease show reduced levels of Sel M, 
which could mean that this selenoprotein plays a protective role in the development of 
Alzheimer’s disease (Hwang, Cho et al. 2005). 
Sel P knockout mice have movement disorders and seizures when given selenium-restricted 
diets from their birth (Hill, Zhou et al. 2003; Schomburg, Schweizer et al. 2003; Kutluhan, 
Naziroglu et al. 2009). Rats on selenium deficient diets have an increased risk of seizures 
and neuronal loss, further providing evidence that selenium can help prevent seizures. 
Because epilepsy is characterized by neuronal loss resulting from pro-apoptotic factors in 
association with oxidative stress (Savaskan, Brauer et al. 2003), selenium might help 
alleviate the underlying causes of brain injury that precipitate seizures.  
5. Nutrigenomics perspectives 
There is much evidence that speculates on the genetic aspect of epilepsy (Rees 2010; Sisodiya 
and Mefford 2011). Nonetheless, since epilepsy is a syndrome and not a disease, the cause of 
seizures in epileptics varies widely. Furthermore, even if epilepsy could be divided into 
groups based on the respective, underlying cause, it would still be difficult to determine the 
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genetic influence because of changes across clinical subgroups and amongst families. 
However, some types of epilepsy have been shown to have strong genetic components 
(Greenberg and Subaran 2011): 1) partial epilepsy has been linked to chromosome 10 q; 2) 
benign familial neonatal convulsions have been mapped to chromosome 20 q and another 
locus found on 8q; 3) a progressive form of myoclonus epilepsy has been localized to 
chromosome 21 q; 4) juvenile myoclonic epilepsy has been associated with regions of 
chromosome 6. Interestingly, the types of epilepsy syndromes that have genetic linkage 
evidence are a very small proportion of all epilepsy cases and no genetic basis has been 
found for most types of epilepsy.  
Nutrigenomics is the study of how nutrition impacts the variation of gene expression across 
individuals. Seeing as how genetically diverse individuals are, it would stand to reason that 
individualized diets based on a person’s genetic background can contribute to better overall 
health. Nutrigenomic approaches will become increasingly necessary in treating chronic 
diseases, including epilepsy. In the future it is expected that we will uncover genetic 
evidence that explains why certain people have different responses to similar diet, and how 
such variations help alleviate neuronal disorders.  
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